Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volociximab and Erlotinib in NSCLC
NCT00278187Phase 2Unknown
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jul 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of volociximab in non-small cell lung cancer (NSCLC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Objective Response Rate. Status: unknown.
02
Drugs
volociximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00278187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00278187.